Drug Design

Edited by: NEERAJA SANKARAN P.Y.S. Lam, P.K. Jadhav, C.J. Eyermann, C.N. Hodge, Y. Ru, L.T. Bacheler, J.L. Meek, M.J. Otto, M.M. Rayner, Y.N. Wong, C-H. Chang, P.C. Weber, D.A. Jackson, T.R. Sharpe, S. Erickson- Viitanen, "Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors," Science, 262:380-4, 1994. (Cited in 46 publications through May 1995) Comments by Patrick Y.S. Lam, DuPont Merck Pharmaceutical Co., Wilmington, Del. Patrick Y.S. Lam, a principal

Neeraja Sankaran
Jun 25, 1995

Edited by: NEERAJA SANKARAN
P.Y.S. Lam, P.K. Jadhav, C.J. Eyermann, C.N. Hodge, Y. Ru, L.T. Bacheler, J.L. Meek, M.J. Otto, M.M. Rayner, Y.N. Wong, C-H. Chang, P.C. Weber, D.A. Jackson, T.R. Sharpe, S. Erickson- Viitanen, "Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors," Science, 262:380-4, 1994. (Cited in 46 publications through May 1995)

Comments by Patrick Y.S. Lam, DuPont Merck Pharmaceutical Co., Wilmington, Del.

Patrick Y.S. Lam, a principal research scientist in the department of chemical and physical sciences at the DuPont Merck Pharmaceutical Co. in Wilmington, Del., notes that the findings reported in this paper came about through the teamwork of computational and synthetic chemists, as well as biologists and crystallographers. Combining forces, the scientists designed and synthesized a novel type of inhibitor for the protease enzyme of HIV.

"HIV protease is an essential enzyme that the virus uses to process proteins in order to...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?